Compare Stocks: APRE, GOSS, ALGS, and CNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.24 +1.4%	$5.79	$3.98 ▼ $13.69	$32.72M	2.34	49,614 shs	21,338 shs
APRE Aprea Therapeutics	$0.76 +1.3%	$0.72	$0.55 ▼ $1.69	$9.57M	1.54	594,476 shs	79,984 shs
CNTX Context Therapeutics	$0.37 -4.0%	$0.49	$0.34 ▼ $3.62	$33.82M	1.69	1.71 million shs	1.12 million shs
GOSS Gossamer Bio	$10.73 -10.1%	$13.11	$9.10 ▼ $309.60	$31.48M	2	302,671 shs	529,471 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+0.38%	-18.63%	-0.76%	-43.17%
APRE Aprea Therapeutics	0.00%	-1.82%	+18.72%	+6.28%	-49.34%
CNTX Context Therapeutics	0.00%	+5.05%	-29.17%	-41.75%	-57.93%
GOSS Gossamer Bio	0.00%	0.00%	-14.84%	-20.16%	-95.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.24 +1.4%	$5.79	$3.98 ▼ $13.69	$32.72M	2.34	49,614 shs	21,338 shs
APRE Aprea Therapeutics	$0.76 +1.3%	$0.72	$0.55 ▼ $1.69	$9.57M	1.54	594,476 shs	79,984 shs
CNTX Context Therapeutics	$0.37 -4.0%	$0.49	$0.34 ▼ $3.62	$33.82M	1.69	1.71 million shs	1.12 million shs
GOSS Gossamer Bio	$10.73 -10.1%	$13.11	$9.10 ▼ $309.60	$31.48M	2	302,671 shs	529,471 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+0.38%	-18.63%	-0.76%	-43.17%
APRE Aprea Therapeutics	0.00%	-1.82%	+18.72%	+6.28%	-49.34%
CNTX Context Therapeutics	0.00%	+5.05%	-29.17%	-41.75%	-57.93%
GOSS Gossamer Bio	0.00%	0.00%	-14.84%	-20.16%	-95.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	634.73% Upside
APRE Aprea Therapeutics	2.40	Hold	$3.07	303.56% Upside
CNTX Context Therapeutics	2.70	Moderate Buy	$6.17	1,575.27% Upside
GOSS Gossamer Bio	2.22	Hold	$256.00	2,285.83% Upside

Current Analyst Ratings Breakdown

Latest APRE, GOSS, ALGS, and CNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/13/2026	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$3.00
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	CNTX Context Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	14.93	N/A	N/A	$8.67 per share	0.60
APRE Aprea Therapeutics	$290K	32.99	N/A	N/A	$1.52 per share	0.50
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
GOSS Gossamer Bio	$53.29M	0.59	N/A	N/A	($42.43) per share	-0.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
APRE Aprea Therapeutics	-$12.60M	-$1.08	N/A	N/A	N/A	-4,405.59%	-47.60%	-40.97%	11/11/2026 (Estimated)
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	11/4/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$56.00	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)

Latest APRE, GOSS, ALGS, and CNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	APRE Aprea Therapeutics	-$0.1775	-$0.07	+$0.1075	-$0.07	$0.25 million	N/A
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
APRE Aprea Therapeutics	N/A	13.56	13.56
CNTX Context Therapeutics	N/A	5.81	5.81
GOSS Gossamer Bio	N/A	0.53	0.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
APRE Aprea Therapeutics	34.19%
CNTX Context Therapeutics	14.03%
GOSS Gossamer Bio	81.23%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
APRE Aprea Therapeutics	10.49%
CNTX Context Therapeutics	4.80%
GOSS Gossamer Bio	3.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	82	6.24 million	5.76 million	No Data
APRE Aprea Therapeutics	8	12.59 million	11.27 million	No Data
CNTX Context Therapeutics	15	91.88 million	87.47 million	Not Optionable
GOSS Gossamer Bio	162	2.93 million	2.82 million	Optionable

APRE, GOSS, ALGS, and CNTX Headlines

Recent News About These Companies

Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of "Hold" from Analysts

September 20 at 4:28 AM | americanbankingnews.com

Wall Street Zen Downgrades Gossamer Bio (NASDAQ:GOSS) to Sell

September 20 at 1:12 AM | americanbankingnews.com

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

September 16, 2026 | businesswire.com

Gossamer Bio consensus price target increased by 4,500% to $135.13

September 15, 2026 | msn.com

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

September 12, 2026 | tmcnet.com

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

September 12, 2026 | tmcnet.com

Wall Street Zen Upgrades Gossamer Bio (NASDAQ:GOSS) to Hold

September 12, 2026 | americanbankingnews.com

Gossamer Bio Stock Falls 6% After 1-For-80 Reverse Stock Split

September 11, 2026 | rttnews.com

Gossamer Bio (NASDAQ:GOSS) Hits New 12-Month Low - What's Next?

September 11, 2026 | marketbeat.com

Graphique Statique Gossamer Bio, Inc.

September 9, 2026 | zonebourse.comZ

Gossamer Bio to Present at Cantor Global Healthcare Conference

September 4, 2026 | businesswire.com

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

August 28, 2026 | finance.yahoo.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS) and Biohaven Ltd. (BHVN)

August 27, 2026 | theglobeandmail.com

Gossamer Bio Amends Charter for New Preferred Financing

August 26, 2026 | tipranks.com

Gossamer Bio announces $250m in funding to advance seralutinib

August 24, 2026 | finance.yahoo.com

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

August 21, 2026 | uk.finance.yahoo.com

Gossamer Bio (NASDAQ:GOSS) Funding Move Signals Biotech Shift

August 21, 2026 | kalkinemedia.comK

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

August 21, 2026 | finance.yahoo.com

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

August 21, 2026 | finance.yahoo.com

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

August 13, 2026 | zacks.com

Gossamer Bio: Q2 Earnings Snapshot

August 13, 2026 | sfgate.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, GOSS, ALGS, and CNTX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$5.24 +0.07 (+1.35%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.15 -0.09 (-1.72%)

As of 09/18/2026 07:30 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Aprea Therapeutics NASDAQ:APRE

$0.76 +0.01 (+1.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.75 -0.01 (-1.83%)

As of 09/18/2026 07:30 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Context Therapeutics NASDAQ:CNTX

$0.37 -0.02 (-3.99%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.38 +0.01 (+2.15%)

As of 09/18/2026 07:30 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Gossamer Bio NASDAQ:GOSS

$10.73 -1.21 (-10.13%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.12 +0.40 (+3.68%)

As of 09/18/2026 07:44 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APRE, GOSS, ALGS, and CNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APRE, GOSS, ALGS, and CNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APRE, GOSS, ALGS, and CNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, GOSS, ALGS, and CNTX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Aprea Therapeutics NASDAQ:APRE

Context Therapeutics NASDAQ:CNTX

Gossamer Bio NASDAQ:GOSS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APRE, GOSS, ALGS, and CNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APRE, GOSS, ALGS, and CNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APRE, GOSS, ALGS, and CNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, GOSS, ALGS, and CNTX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Aprea Therapeutics NASDAQ:APRE

Context Therapeutics NASDAQ:CNTX

Gossamer Bio NASDAQ:GOSS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools